Novus International Inc., intelligent nutrition company, has entered a strategic co-development partnership with innovative biotechnology company Resilient Biotics to create a novel feed solution that supports immune health and helps reduce the risk of respiratory challenges in pigs. 

“Respiratory challenges like porcine reproductive and respiratory syndrome (PRRS), porcine respiratory disease complex (PRDC) and others create a strain on pig health and cost the industry billions each year in production loss. The industry eagerly wants to find unique ways to optimize pig health and impact the risk of these challenges,” said Gaurav Shah, Novus associate director of innovation and business development. “Novus and Resilient Biotics are working to address these challenges in a way that hasn’t been done before. We’re very excited to work with Resilient Biotics to develop a new kind of feed solution that can make a huge impact on the swine industry.” 

Resilient Biotics is a North Carolina-based biotechnology company pioneering innovative microbiome-based strategies to improve animal health. The joint development effort will leverage the company’s proprietary microbiome product discovery platform, custom databases built for understanding the role of microbial strains in porcine respiratory health, and an extensive collection of swine microbials to develop precision solutions for swine. 

Related:Of pigs and men: Best-laid plans for prevention and control of African swine fever

“Resilient Biotics is excited to partner with Novus to bring novel microbial solutions to the market. The joint development effort will leverage Resilient Biotics’ deep knowledge of the swine respiratory microbiome and proven discovery platform to identify proprietary swine microbials that improve host health and boost defense against respiratory pathogens,” said Chris Belnap, Resilient Biotics chief executive officer and co-founder.

Both companies are dedicated to creating a product that will provide consistent, measurable benefits. The new product is expected to take three years to develop, including extensive testing to ensure its efficacy.

This is the latest product development project to align with Novus’s vision to help customers solve real-world problems so animals can reach their full potential. The company is also working with Ginkgo Bioworks to develop a new enzyme solution. In addition, Novus acquired BioResource International Inc. in 2024 to optimize its CIBENZA Enzyme Feed Additive product line and take advantage of the company’s fermentation expertise.

“The partnership with Resilient Biotics is another example of how important innovation and developing new technologies is to Novus and how – through science – we’re providing solutions that make the animal agriculture industry more sustainable,” NOVUS president and CEO Dan Meagher said. “Every year meat, milk and egg producers are expected to do more with less. We’re here to help our customers meet their goals through intelligent nutrition built on advanced technology.”

Related:Use or non-use of treatment therapies for swine respiratory disease in finishing pigs

Novus provides solutions for the animal agriculture industry, offering trace minerals, nutritional enzymes, feed digestibility and meat quality solutions, gut health products and methionine sources that help animals reach their full potential.

Resilient Biotics develops microbiome-based solutions to improve livestock respiratory health. By harnessing cutting-edge microbial discovery and development technologies, the company aims to address critical challenges in animal health and support the industry’s efforts to produce food more sustainably.